Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Gamechanger-Deal am Horizont: Entscheidende Nachrichten in 2025 erwartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40W1C | ISIN: US2936025046 | Ticker-Symbol:
NASDAQ
23.04.25
22:00 Uhr
3,670 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENSYSCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ENSYSCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ENSYSCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEnsysce Biosciences announces exercise of warrants for $2.2M gross proceeds1
MiEnsysce Biosciences Stock Doubles In One Trading Session - Here's Why1
MiEnsysce Biosciences to raise $2.2 million through warrant exercise1
ENSYSCE BIOSCIENCES Aktie jetzt für 0€ handeln
MiEnsysce Biosciences sammelt 2,2 Millionen US-Dollar durch Optionsscheinausübung-
MiEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds189SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief...
► Artikel lesen
MiEnsysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder116~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc....
► Artikel lesen
16.04.Ensysce Biosciences files to sell 652,439 shares of common stock for holders1
15.04.Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study172~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...
► Artikel lesen
31.03.Ensysce Biosciences, Inc. - 8-K, Current Report2
31.03.Ensysce Biosciences raises $1.1 million in stock sale2
31.03.Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules134SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
18.03.Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain165~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce...
► Artikel lesen
10.03.Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results280Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPARGroundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire /...
► Artikel lesen
10.03.Ensysce Biosciences, Inc. - 10-K, Annual Report2
10.03.Ensysce Biosciences, Inc. - 8-K, Current Report3
05.03.Ensysce Biosciences to Participate in the 37th Annual ROTH Conference206SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
05.02.Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment211~ Positive Enrollment Progress and Safety Data ~~ FDA Attention Establishes Momentum in the Pain Treatment Space ~ SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)...
► Artikel lesen
04.02.Ensysce Biosciences, Inc. - 8-K, Current Report-
22.01.Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR258~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...
► Artikel lesen
08.01.Ensysce Biosciences Inc.: Ensysce Biosciences Issues Annual Shareholder Letter263~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence...
► Artikel lesen
Seite:  Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1